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Wild-type human chorionic gonadotropin (hCG)
has been used as a contraceptive vaccine. How-
ever, extensive sequence homology with LH elicits
production of cross-reactive antibodies. Substitu-
tion of arginine68 of the -subunit (hCG) with glu-
tamic acid (R68E) profoundly reduces the cross-
reactivity while refocusing the immune response to
the hCG-specific C-terminal peptide (CTP). To in-
vestigate the molecular basis for this change in
epitope usage, we immunized mice with a plasmid
encoding a truncated hCG-R68E chain lacking
the CTP. The animals produced LH-cross-reactive
antibodies, suggesting that the refocused immu-
nogenicity of R68E is a consequence of epitope
masking by a novel disposition of the CTP in the
mutant rather than a structural change in the
cross-reactive epitope region. This explanation
was strongly supported by surface plasmon reso-
nance analysis using a panel of anti-hCG-specific
and anti-hCG/LH cross-reactive monoclonal an-
tibodies (mAbs). Whereas the binding of the LH
cross-reactive mAbs to hCG-R68E was elimi-
nated, mAbs reacting with hCG-specific epitopes
bound to hCG and hCG-R68E with identical af-
finities. In a separate series of experiments, we
observed that LH cross-reactive epitopes were si-
lent after immunization with a plasmid encoding a
membrane form of hCG-R68E, as previously ob-
served with the soluble mutant protein itself. In
contrast, the plasmid encoding the soluble se-
creted form of hCG-R68E evoked LH cross-reac-
tive antibodies, albeit of relatively low titer, sug-
gesting that the handling and processing of the
proteins produced by the two constructs differed.
(Molecular Endocrinology 19: 1803–1811, 2005)
HUMAN CHORIONIC gonadotropin (hCG) is amember of the glycoprotein hormone family,
which also includes LH, FSH, and TSH. The glycop-
rotein hormones are heterodimeric molecules consist-
ing of a common -chain noncovalently associated
with a hormone-specific -chain. In a healthy woman,
biologically active hCG is only present in significant
concentrations during pregnancy where it stimulates
the corpus luteum to produce progesterone and es-
trogen required for sustaining the implanted embryo.
Incubation of marmoset embryos with hCG-specific
antibodies prevents implantation (1), and hCG is con-
sidered an antifertility vaccine candidate (2–5). Phase
II trials of a heterospecies vaccine consisting of an
ovine -chain and hCG -chain coupled to tetanus
toxoid or diphtheria toxoid resulted in only one preg-
nancy among 1224 cycles in those immunized women
producing circulating anti-hCG antibodies above 50
ng per ml (2). However, due to the 85% sequence
homology between the first 110 amino acid residues of
hCG and LH, most of the anti-hCG antibodies pro-
duced cross-reacted with LH (3). Although no adverse
effects of the LH-cross-reactive antibodies were ob-
served in the cohort studied (3), the long-term pres-
ence of such antibodies may cause undesired side
effects.
With the aim of producing a potentially safer hCG-
based vaccine, we have constructed a series of hCG
mutants in which amino acid residues at presumed LH
cross-reactive epitope regions have been substituted
(6). One of these mutants, hCG-R68E, with arginine68
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substituted with glutamic acid, failed to bind all tested
LH-cross-reactive monoclonal antibodies (mAbs)
without apparently affecting the natural folding of the
molecule, as judged by the ability of the conformation-
dependent hCG-specific mAbs to recognize the pro-
tein (6). Baculovirus-produced hCG-R68E elicited
antibodies with minimal LH cross-reactivity in both mice
and rabbits (7, 8). The antibodies produced were pre-
dominantly directed against sequences present on the
hCG-specific C-terminal peptide region (hCGCTP;
amino acids 113–145), which is missing in LH and has
been generated during evolution by a read-through
event. This peptide region adopts a free-floating entropy-
rich conformation in hCG (9) and consequently is poorly
immunogenic (7, 8). We hypothesized that glutamic ac-
id68 in the mutant forms a salt bridge with one or more of
the basic amino acid residues present in the hCGCTP,
thus providing the hCGCTP with a defined conforma-
tion that creates a new and more immunogenic loop.
We have used DNA immunization and analysis by
surface plasmon resonance to further probe the struc-
ture of hCG-R68E. We show here that truncation of
the CTP element of hCG-R68E (hCG-R68E-CTP)
restores the immunodominance of the LH-cross-reac-
tive epitope region so that mice immunized with a
plasmid expressing hCG-R68E-CTP produce anti-
bodies that recognize hCG, LH, and hCG-R68E
equally well. Biosensor analysis is often used to de-
termine the thermodynamics of antibody-antigen in-
teractions. Even subtle changes in the structure of the
antigen can have profound consequences for the ki-
netics of formation or dissociation of the protein-pro-
tein complexes. Optical biosensor analysis of the con-
formational integrity of hCG-R68E confirmed that
whereas LH-cross-reactive epitopes were inaccessi-
ble in the mutant, hCG-specific epitopes adjacent to
the cross-reactive epitope region were unaffected by
the substitution. This is consistent with our proposed
model postulating formation of a salt bridge between
glutamic acid68 and a basic residue on the CTP, which
masks the LH-cross-reacting epitopes. The identity of
the charge on CTP remains to be determined, but both
K122 and R133 contribute to the formation of the loop
structure.
RESULTS
Immunization
BALB/c mice immunized with expression plasmids en-
coding either membrane-attached (pCDNA3-hCG-
TM) or soluble (pCDNA3-hCG-His6) forms of hCG
(Fig. 1) produced antibodies that bind equally well to
holo-hCG, recombinant hCG produced in baculovi-
rus (Bac-hCG-WT), and the mutant hCG-R68E pro-
duced in baculovirus (Bac-hCG-R68E) and cross-
reacted with LH (Fig. 2). This contrasts with the results
obtained after immunization with pCDNA3-hCG-
R68E. As expected, mice immunized with DNA encod-
ing a membrane-attached form of hCG-R68E
(pCDNA3-hCG-R68E-TM) produced antibodies that
bind well to Bac-hCG-R68E. The sera from these
mice reacted poorly with holo-hCG and the free Bac-
hCG subunit and showed no cross-reactivity with LH
(Fig. 2), consistent with the results obtained after in-
tranasal immunization of mice with purified Bac-
hCG-R68E mixed with Escherichia coli heat-labile
protein (7). This contrasts with the result obtained in
mice immunized with pCDNA3-hCG-R68E-His6 en-
coding a secreted form of hCG-R68E, which resulted
in antibodies that bind to Bac-hCG but less so to
holo-hCG and LH although they reacted more strongly
with Bac-hCG-R68E.
This is consistent with our proposed structure of
hCG-R68E, which envisages the normally entropy-
rich hCGCTP becoming conformationally fixed by
formation of a salt bridge between glutamic acid68 and
one or more of the basic residues present in the
hCGCTP (8, 10). This model predicts that mice im-
munized with a truncated hCG-R68E molecule with-
out CTP (hCG-R68E-CTP) would produce antibod-
ies that bind to hCG, and notably LH, equally well as to
hCG-R68E itself. As shown in Fig. 2, mice immunized
with pCDNA3-hCG-R68E-CTP did elicit antibodies
that bind equally well to holo-hCG, LH, and Bac-
hCG. Although the antigen-specific IgGs react stron-
Fig. 1. Diagram of the hCG-Related Immunogens Used
The N-linked and the O-linked glycosylation sites are indi-
cated with an open and a solid arrow, respectively. The
numbering of amino acid residues relates to hCG, and the
positions of the mutated residues are indicated in italic.
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ger with Bac-hCG-R68E, there was no statistical dif-
ference [P  0.11, paired Student’s t test (LH coating
vs. Bac-hCG coating); P  0.09, paired Student’s t
test (LH coating vs. recombinant hCG coating)] be-
tween the results obtained with Bac-hCG, holo-hCG,
or LH. This supports the hypothesis that the CTP
attains a conformation in hCG-R68E, which blocks
the accessibility of cognate B cells to the cross-reac-
tive epitope region on the body of the hCGmolecule.
Thermodynamic Analysis
To probe further into the conformation of hCG-R68E,
we used surface plasmon resonance to determine the
association and dissociation rates and affinity con-
stants of selected hCG-reactive mAbs, because even
modest structural changes in the overall conformation
of the core domain of hCG as a result of the glutamic
acid68 substitution would affect the thermodynamic
properties of the antibodies’ binding. For this analysis,
a panel of mAbs directed to LH-cross-reactive and
hCG-specific epitopes (11, 12) were selected (Table
1). INN-22 and INN-58 have specificity for the immu-
nodominant LH-cross-reactive epitopes, 2 and 5
(12), respectively. As representative for the hCG-spe-
cific mAbs, INN-2, INN-64, and INN-68, which bind to
1, 6, and 7 (12), respectively, were selected.
Epitope 1 is accessible on holo-hCG and includes
among its contact residues arginine10 and arginine60
close to the cystine knot (13), whereas 6 and 7 are
both located in the interface between the - and
-subunit and are inaccessible on holo-hCG (12).
Epitope 6 is spatially close to lysine20, glutamic ac-
id21, glycine22, and glycine75 (6), whereas epitope 7 is
affected by mutations of the residues in position 61
and 89 (13).
To reduce cross-linking by the bivalent IgGs, Fab
fragments of each mAb were generated by papain
digestion. The Fab fragments obtained from the indi-
vidual Igs contained limited but varying amounts of
undigested Igs in the samples. Although the calculated
equilibrium constant therefore cannot be interpreted
as an absolute value, the data obtained for wild-type
mutant hCG can nevertheless be compared, be-
cause the same Fab/antibody ratio was used for both
proteins.
Figure 3 shows the sensorgrams for the binding of
INN-2, INN-22, INN-58, INN-64, and INN-68 to Bac-
hCG-WT and Bac-hCG-R68E, and the resulting as-
sociation rate constant (ka), dissociation rate constant
(kd), and apparent dissociation equilibrium constant
KD are summarized in Table 2. The five Fabs recog-
nized Bac-hCG-WT with a dissociation equilibrium
constant varying between 8.2  108 M for INN-2 and
0.7  108 M for INN-68 Fab. This compares with the
affinities of the mAbs determined by saturation or
competitive RIA (14, 15). This demonstrates that the
recognition of the five spatially distinct antigenic sites
on Bac-hCG-WT by these antibodies has not been
affected dramatically by production of the hCG sub-
unit in insect cells, indicating that differences in post-
translational modifications, such as glycosylation, in
insect cells do not substantially modify the overall
three-dimensional structure of the protein.
The glutamic acid68 substitution in Bac-hCG-R68E
abrogates the binding of the LH-cross-reactive Fabs
INN-22 and INN-58, whereas binding of the Fabs to
the hCG-specific epitopes, 1, 6, and 7, was unaf-
fected by the mutation (Fig. 3 and Table 2) in agree-
ment with the results obtained by flow cytometric anal-
ysis of transiently transfected COS-7 cells (6). At the
same concentration at which the cross-reactive Fabs
(INN-22 and INN-58) reacted with Bac-hCG-WT,
minimal binding to Bac-hCG-R68E was observed.
Fig. 2. The Level of hCG-Specific Antibodies after Immuni-
zation with Plasmid DNA
Female BALB/c mice (n  5) were immunized with 50 g
plasmid DNA expressing membrane-attached (TM) or se-
creted (His) hCG or hCG-R68E or truncated hCG-R68E
(hCG-R68E-CTP) devoid of the CTP. Sera (dilution
1:50) were analyzed in ELISA using plates coated with pro-
teins as indicated, and the results are expressed as optical
density  SD.
Table 1. Specificities of the mAbs Used in the Present
Study
mAb Epitope Epitope Properties
INN-2 1 hCG specific
INN-22 2 hCG/LH cross-reactive
INN-58 5 hCG/LH cross-reactive
INN-64 6 hCG specific (-interface)
INN-68 7 hCG specific (-interface)
Charrel-Dennis et al. • Conformation of hCG-R68E Mutant Mol Endocrinol, July 2005, 19(7):1803–1811 1805
Indeed, the association rates of the two cross-reactive
Fabs were very similar to that obtained for the isotype-
matched control antibody (data not shown). In con-
trast, the 6 (INN-64) and 7 (INN-68) epitopes lo-
cated at the interface between the - and -subunit
remained unchanged by the mutation. The association
and dissociation rate constants for the binding of each
of these antibodies to Bac-hCG-WT and Bac-hCG-
R68E were not statistically different (Table 2). Both 6
and 7 are spatially relatively adjacent to the cross-
reactive epitope region recognized by INN-22 and
INN-58. Thus the fact that the binding affinities of
INN-64 and INN-68 are unaffected by the glutamic
acid68 substitution implies that the overall structure of
hCG is maintained.
The 1-specific INN-2 antibody was previously
thought to recognize the wild-type and mutant protein
equally well (6). The biosensor analysis showed, how-
ever, a slightly higher association rate (ka  2.5 
104 M1 sec1) for INN-2 binding to the mutant protein
than that observed for the binding to Bac-hCG-WT
(ka 1.5 10
4 M1 sec1). Nonetheless, the complex
formed with the mutant protein appeared to be less
stable with a kd  2.7  10
3 sec1 for Bac-hCG-
R68E compared with kd  1.8  10
3 sec1 for the
wild-type form of hCG (Table 2). Overall, the affinity
of binding was significantly greater for the wild-type
protein (KD  8.2  10
8 M) compared with that of the
mutant (KD 11.1 10
8 M; P 0.001). Nevertheless,
the difference in free energy changes between INN-2
binding to the mutant and the wild-type protein was
minimal (G  0.163 kcal/mol). The binding of INN-2
to hCG involves residues arginine10 and arginine60
(13). It seems unlikely, however, that an amino acid
substitution localized more than 30Å away from the 1
epitope, which does not modify the conformation of
more proximal epitopes, could affect the recognition
pattern of this epitope. However, the formation of a
salt bridge between the glutamic acid68 and the basic
residues of the hCGCTP could affect the spatial ori-
Fig. 3. Sensorgram Showing the Binding of Fabs to Bac-hCG or Bac-hCG-R68E
Recombinant Bac-hCG or Bac-hCG-R68E was bound to Ni2-charged nitrilotriacetic acid sensor chips at a concentration
equivalent to 500 RU. A solution (50 l) containing a predetermined dilution of the appropriate Fab (INN-2; INN-22; INN-58;
INN-64; and INN-68) was passed onto the chip at a rate of 20 l/min. The sensorgrams were corrected for the constant release
of His-tagged recombinant protein, normalized, and overlaid. *, Sensorgrams obtained with Bac-hCG; #, sensorgrams obtained
with Bac-hCG-R68E.
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entation of the oligosaccharide antennae, resulting in
an increase in the association rate of INN-2. The in-
creased instability of the complex formed with the
mutant protein could be related to some steric
hindrance of the antibody by the fixed CTP of
hCG-R68E.
CTP Mutations
Our model predicts that the presence of an acidic
residue (glutamic acid) at position 68 of hCG
changes the chemical characteristic of this region of
the protein structure. Normally this region of the struc-
ture is flat with two protruding amino acid residues,
R68 and R74, approximately 10Å apart, both with a net
positive charge. The substitution R68E changes both
the shape and charge of this area of hCG, which is
part of the cross-reactive epitope, although it is un-
likely to greatly modify the folded structure of the
protein that is tethered by the disulfide C23-C72. A
working hypothesis for the masking of the cross-re-
active epitopes is that R68E forms a salt bridge with
one or more of the basic amino acid residues in the
CTP. There are three possible candidate residues,
R114, K122, and R133 (Fig. 4). Both R114 and R133 have
negatively charged residues in relative close proximity
within the peptide, which could form additional
charged interactions with R74 on the same surface.
R133 is an unlikely candidate as it forms part of the
epitope for mAb OT3A (amino acids 133–139) the
binding of which has been shown to be unaffected in
the R68E mutant (6). R114 is also in doubt if the -sub-
unit disulfide C26-C110 is formed as this would tether
the CTP on the opposite side of the -subunit and R114
would be too far away from R68E to form a salt bridge.
However if this disulfide were not formed (due to the
absence of the -subunit), then the flexibility of the
“seat belt” region of the -subunit would probably
permit R114 to form a salt bridge. In an attempt to
identify the putative donor residue for the postulated
salt bridge with R68E, we selectively substituted K122
and R133 on hCG-R68E with glutamine individually or
together (Fig. 1) and immunized groups of BALB/c
mice with plasmids precipitated onto gold particles.
As shown in Fig. 5, the strongly CTP-focused and
reduced hLH cross-reactive antibody response ob-
tained with pCDNA3-hCG-R68E-TM was not ob-
tained after immunization with any of the three CTP
mutants: pCDNA3-hCG-R68E-K122Q-TM, pDNA3-
hCG-R68E-R133Q-TM, or pCDNA3-hCG-R68E-
K122Q-R133Q-TM. The immune response with each
of the CTP mutants was similar to that obtained after
immunization with pCDNA3-hCG-TM. This con-
firmed that the conformation of CTP is fixed in hCG-
R68E but that both K122 and R133 contribute to
establish this conformational change.
DISCUSSION
A single arginine68 to glutamic acid substitution in
hCG dramatically alters the antigenicity and immu-
nogenicity of the mutant molecule. The immunodom-
inant LH cross-reactive epitope cluster on hCG has
been defined by several mAbs and comprises several
epitopes (2, 3, 4, and 5) (12) that may share one
or more contact residues as we have previously sug-
gested (16). Representative mAbs defining each of
these epitopes fail to bind to recombinant hCG-R68E
expressed in either COS7 cells (6) or insect cells (Table
2). We have identified, however, one CTP-reactive
mAb (2F4/3) that reacts more avidly with hCG-R68E
than with hCG or hCG (7), suggesting that the glu-
tamic acid68 substitution affects the conformation of
the normally entropy-rich, free-floating CTP. Indeed,
immunogenicity studies with baculovirus-derived
Table 2. Kinetic Parameters for Reaction of Fab Fragments of the INN-2, INN-22, INN-58, INN-64, and INN-68 Antibodies
with Bac-hCG-WT and Bac-hCG-R68E
Antibody Antigen Apparent KD(108 M)
ka
(104 M1 sec1)
kd
(103 sec1) WT/R68E
a Gb
(kcal/mol)
Gc
(kcal/mol)
INN-2 Fab WT 8.2  1.1d 1.5  0.2 1.8  0.37 P  0.0003a 9.6 0.163
R68E 11.1  2.1 2.5  0.6 2.7  0.5 9.4
INN-22 Fab WT 1.8  0.4 3.6  0.7 0.6  0.05 10.5
R68E N.A. N.A. N.A.
INN-58 Fab WT 1.1  0.2 12.1  1.9 1.3  0.1 10.8
R68E N.A. N.A. N.A.
INN-64 Fab WT 4.4  1.1 6.6  1.4 2.8  0.2 P  3.7 10.0 0.002
R68E 4.2  1.6 5.4  1.1 2.3  0.1 10.0
INN-68 Fab WT 0.7  0.2 2.8  0.6 0.2  0.04 P  0.12 11.0 0.162
R68E 1.1  0.3 2.4  0.6 0.2  0.1 10.9
N.A., Not ascertainable because binding is comparable to isotype control Fab and therefore too low to permit calculation of
binding constants; WT, wild type.
a Student’s t test was used to calculate the P value for KD.
b The variation in free energy upon binding was determined using: G  RT ln(ka/kd).
c The difference in free energy changes between the mutant and the wild-type protein were calculated as: G GR68E GWT.
d  SD.
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hCG-R68E in both mice (7) and rabbits (8) show that
the immune response is refocused toward epitope(s)
present on the CTP at the expense of the major LH
cross-reactive epitope normally used by hCG/hCG
as also demonstrated in the present study after DNA
immunization of mice with pCDNA3-hCG-R68E-TM
or pCDNA3-hCG-R68E-His6 (Figs. 2 and 5).
To explain these findings we have proposed that the
presence of an acidic residue (glutamic acid) at posi-
tion 68 of hCG changes the chemical characteristic
of this region of the protein structure. The mutation
R68E could potentially permit the formation of an in-
ternal salt bridge between the glutamic acid and a
positive charge associated with the CTP, thereby fix-
ing the structure of the CTP by forming a new loop
structure. Elimination of the CTP on the hCG-R68E
immunogen (hCG-R68E-CTP) elicited antibodies that
reacted equally well with hCG, LH, and Bac-hCG-R68E
in contrast to antibodies produced after immunization
with pCDNA3-hCG-R68E-TM or pCDNA3-hCG-
R68E-His6. The presence of a new loop structure is
further supported by real-time binding kinetics of mAbs
to wild-type and mutant Bac-hCG using surface plas-
mon resonance. Whereas the 2- and 5-specific LH
cross-reactive mAbs fail to bind Bac-hCG-R68E, the
mAbs INN-64 and INN-68, specific for epitopes 6 and
7, which include residues located both on loop 1 and
loop 3 of the -subunit (6), bind to the wild-type and the
mutant subunit with nearly identical association and dis-
sociation rates (Table 2). This demonstrates that glu-
tamic acid68 does not introduce major structural
changes that affect the relative spatial arrangement of
loops 1 and 3, which present these two epitopes. Rather,
it seems more probable that a salt bridge might be
formed between glutamic acid68 and one or more of the
basic residues on CTP (K122 and R133), thereby masking
the entire cross-reactive epitope cluster and eliminating
their accessibility for both isolated LH-cross-reactive
mAbs and potential B cell receptors with specificity for
this region of hCG. However, both K122 and R133 appear
important for establishing this additional loop structure,
because selectively substituting either of these residues
with a noncharged glutamine abolished the CTP-loop
structure of hCG-R68E. It is surprising that both these
mutants have an effect, ruling out a simple salt bridge
between E68 and one of the residues. Both K122 and R133
occupy rather similar positions in sequence (i.e. both
follow a serine that is O-linked glycosylated in the CTP),
so substituting either of these residues with the neutral
glutamine may alter the O-linked glycans on the CTP.
Equally, these residues may be important in fixing the
CTP structure in hCG-R68E but not directly via an
interaction with residue 68. Clearly, a more detailed
structural analysis of hCG-R68E is required to deter-
mine the structure of the CTP in this mutant protein and
the role of the individual amino acids in interactions with
the main body of hCG.
Regarding antibody recognition of the other, non-
CTP but hCG-specific, epitopes we noted less bind-
ing (at a molar basis) of the panel of mAbs to Bac-
Fig. 4. A Ribbon Representation of a Molecular Model of hCG (Based on Protein Data Base Entry 1 HRP) with the -Subunit
(Cyan), -Subunit (Magenta), and Disulfide Bridges (Shown in Yellow)
A chemically sensible conformation of the CTP (not seen in the x-ray structure) is modeled with O-linked carbohydrates shown
in green. The CTP is able to wrap around the -subunit in the R68E mutant forming an interaction that blocks the LH
cross-reactive epitope. Charged amino acid residues of the CTP are labeled.
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hCG-R68E than to wild-type Bac-hCG. Although it
is unclear why this should occur, given that hCG and
Bac-hCG have a tendency to form aggregates, it is
possible that the constrained conformation of the CTP
in hCG-R68E favors structures that make the other
-specific epitopes less accessible on the mutant mol-
ecule than on the wild-type Bac-hCG molecule.
Depending on the antigen, mice DNA-immunized
with a membrane-attached molecule can produce a
greater antibody response compared with mice immu-
nized with plasmids encoding soluble forms of the
antigen, as shown, for example, with influenza virus
hemagglutinin (17). This is not apparent for relatively
weak antigens such as hCG, as shown in Fig. 2,
where the membrane-attached (pCDNA3-hCG-
R68E-TM) and soluble (pCDNA3-hCG-R68E-His6)
forms of the immunogen produce comparable R68E
mutant-specific antibodies. However, immunization of
mice with these two immunogens resulted in differ-
ences in both the magnitude and complexity of the
antibodies reacting with related antigens (Fig. 2).
Whereas mice immunized with pCDNA3-hCG-
R68E-TM predominantly used epitopes specific to
hCG-R68E, consistent with the results obtained after
intranasal immunization of mice with Bac-hCGR68E
(7), immunization with pCDNA3-hCG-R68E-His6 pro-
duced a higher level of antibodies reacting with hCG
and hCG and, to a lesser extent, LH (Fig. 2). The
difference in the response to immunization with the
soluble mutant plasmid, as compared with the mem-
branous form and indeed the soluble mutant protein
itself, presumably reflects differences in the accessi-
bility of the LH cross-reacting epitopes to the cognate
B cell receptors as a result of some variation in the
handling or processing of these immunogens by anti-
gen-presenting cells.
MATERIALS AND METHODS
Immunization
Plasmid pCDNA3 (Invitrogen, Paisley, Scotland, UK) was
used as the backbone plasmid into which the majority of the
hCG fragments were subcloned. Fragments encoding
hCG and hCG-R68E fused with the transmembrane and
cytoplasmic tail of H2-Db (6) were subcloned as HindIII-NotI
fragments to generate pCDNA3-hCG-TM. pCDNA3-hCG-
His6 and pCDNA3-hCG-R68E-His6 were constructed by
subcloning of a HindIII-NotI hCG-His6 fragment from pBac-
hCG-WT and pBac-hCG-R68E-His6 (7). pCDNA3-hCG-
R68E-CTP was made by a PCR amplification using the
5-T7 primer (5-TAATACGACTCACTATAGGG-3) and 3-
primer (5-TGCTCTAGATTAGTGGTGGTGGTGGTGGTGGT-
CGACCAAGGGGTGGTCCTTGGG-3) and subcloning the
PCR product digested with HindIII and SalI into the HindIII-
SalI-digested pLitmus-hCG-His6 and subsequently subc-
loned into pCDNA3 as a HindIII-NotI fragment (Fig. 1).
pCDNA3-hCG-R68E-K122Q-TM and pCDNA3-hCG-
R68E-R133Q-TM were made by PCR amplifications using
5-M13-reverse sequence primer (5-AGCGGATAACAATT-
TCACACAGGA) and for the 3-primers (for the K122E sub-
stitution: 5-GATGGGCTTGGAAGGCTGGGGGGAGGGGCTT-
GTGAGGAAGAGGAGTCCTGGAAG followed by a second PCR
using the 3-primer: 5-CCAGCGTCCTCGAGTTGTGGGAG-
GATCGGG), (for the R133Q substitution: 5-TAACGCCAGCT-
GTTGTGGGAGGATCGGGGTGTCTGAGGGCCCCGGGAGTT-
GGGATGGACTTGGAAGGCTG followed by a second PCRwith
the 3-primer 5-CCAGCGTCCTCGAGTTGTGGGAGGATCGGG)
using pLitmus-hCG-R68E-His6 as template. pCDNA3-
hCG-R68E-	122Q-R133Q-TM was made from hCG-
R68E-K133Q with the same 3-primers used to make hCG-
R68E-R133Q. The final PCR products were digested with
EcoRI and XhoI and subcloned into pLitmus containing the
H2-Kb TM region used previously (6). The recombinant gene
was finally subcloned into pCDNA3 as a HindIII-NotI frag-
ment. All plasmids used to immunize mice were purified using
a QIAGEN endotoxin-free purification kit (QIAGEN, Crawley,
West Sussex, UK).
Female BALB/c mice (6 wk old) in groups of five were
immunized one to three times. For DNA immunization the
recipient animals were injected im with 6.8 g cardiotoxin
(Sigma, Poole, Dorset, UK) in 100 l of 0.15 M PBS (pH 7.4)
6 d before being primed (wk 0) with 50 g plasmid DNA
injected into the cardiotoxin-treated muscles, and an addi-
tional boost of 50 g plasmid DNA was given 2 wk later. After
the injection of the plasmid DNA into the quadriceps, the
muscles were stimulated electrically as described by
Fig. 5. The Relative Levels of Specific Antibodies after
Particle-Mediated DNA Immunization with hCG-R68E that
Contained CTP Substitutions
Female BALB/c mice (n  5) were primed and boosted 4
wk later with 2 g plasmid DNA coated onto 2 mg gold
particles. Sera (dilution 1:50) were analyzed in ELISA using
plates coated with recombinant hCG, LH, and CTP, and the
ratio of mean optical density values for CTP and hCG (upper
panel) and for LH and hCG (lower panel) were plotted.
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Mathiesen (18). Briefly, silver rod electrodes were placed on
the skin at the site of DNA injection, and the muscles were
subjected to eight trains of 1000 pulses delivered at a fre-
quency of 1000 Hz using a Hear 6-bp stimulator (Frederick
Hear, Bowdoinham, ME). Each pulse lasted 400 sec. The
electric field strength was approximately 50 V over 3–4 mm,
and each train was delivered at 2-sec intervals with each train
lasting 1 sec.
For particle-mediated DNA delivery the plasmids (2 g/mg
gold) were precipitated onto 2-m diameter gold particles
(DeGussa Metals Group, South Plainfield, NJ) in the presence
of 0.05 M spermidine (Sigma) and 1 M calcium chloride. The
gold particles were washed three times in absolute alcohol
containing 0.15 M polyvinylpyrrolidone (Sigma), and then ad-
sorbed to the inner surface of Tefzel tubing (TFX Medical,
Inc., Jaffrey, NH) by centrifugal force. The Tefzel tubes were
subsequently cut into 1.27-cm long cartridges and stored
desiccated at 4 C. A cartridge contains 0.5–0.75 g plasmid
DNA/0.5 mg gold particles. The DNA-coated gold particles
were delivered from cassettes at 500 pounds/square inch of
pressure at two sites of shaved abdomen (1.0–1.5 g total
DNA) by particle-mediated DNA delivery using the Helious
Gene Gun (Bio-Rad, Hemel Hempstead, Hertfordshire, UK).
Mice were immunized at wk 0 and received a boost 4 wk
later.
At the end of the experiment, the animals were killed by
exsanguination. All animal experiments were carried out ac-
cording to United Kingdom Home Office guidelines.
Immunoassays
MaxisorpC plates were coated at 4 C overnight with recom-
binant hCG (Sigma), hLH purified from pituitary (a kind gift
from Dr. A. F. Parlow, Harbor-UCLA Medical Center, Tor-
rance, CA), and Bac-hCG and Bac-hCG-R68E purified as
described (7), at 1.0 g/ml with 50 l/well in 0.05 M carbon-
ate-bicarbonate buffer, pH 9.6 (CBB). The plates were
washed three times in PBS containing 0.05% Tween 20
(PBS-T), followed by blocking with 2% dried skimmed milk
powder in CBB overnight at 4 C. After washing three times
with PBS-T, 50 l serum (from the immunized or nonimmu-
nized mice) diluted 100 times in PBS-T was added and in-
cubated for 2 h at 37 C. The plates were washed three times
with PBS-T before goat antimouse IgG alkaline phosphatase-
conjugated polyclonal antibodies (Sigma) were added for 2 h
at 37 C. The substrate p-nitrophenylphosphate in CBB con-
taining 2 mM MgCl2 was added, for 15 min, and the plates
were read at A405 using an MR5000 ELISA plate reader (Dy-
natech Laboratories Ltd., Billinghurst, Sussex, UK).
Production and Purification of Baculovirus-
Produced hCG
The construction of pBac2-hCG-WT and pBac2-hCG-
R68E encoding wild-type hCG (Bac-hCG-WT) and mutant
hCG-R68E (Bac-hCG-R68E) and their viruses has been
described previously (7). Briefly, Bac-hCG-WT and Bac-
hCG-R68E were both extended at the carboxy terminus
with a His6-tag that can be used to capture the proteins on
the sensor chip by chelating to nickel ions. The recombinant
proteins were purified as previously reported (7). The media
from virus-infected High Five cultures infected at a multiplic-
ity of infection of 10 were harvested by centrifugation at 24,
48, and 72 h post infection and analyzed by PAGE and
Western blotting. The concentrations of the recombinant pro-
teins in the supernatants harvested 72 h post infection were
determined using an ELISA and rabbit polyclonal serum di-
rected against the hCGCTP (kindly provided by Dr. Vernon
C. Stevens, Ohio State University, Columbus, OH). The con-
centrations of Bac-hCG-WT and Bac-hCG-R68E superna-
tants were 1–2 g/ml and 2–3 g/ml, respectively, based on
a comparison with hCG (Zymed Laboratories, Inc., South
San Francisco, CA). To determine whether the -subunits
were aggregated in the supernatant, the nondenatured pro-
teins were analyzed by size exclusion chromatography using
the SMART system (Amersham Pharmacia Biotechnology
Ltd., Little Chalfont, Buckinghamshire, UK). Baculovirus su-
pernatants (50 l) were separated on a Sepharose 12 PC
3.2/30 column (bed volume of 2.3 ml) (Amersham Pharmacia
Biotechnology Ltd.) at a speed of 50 l/min. Twenty fractions
of 50 l were collected, and 10% SDS-PAGE and Western
blotting using an hCGCTP-specific rabbit polyclonal serum
were used to determine the presence of recombinant protein
in the fractions. The molecular weight of the hCG subunits
was assessed using a High and a Low Molecular Weight
Calibration kit (Amersham Pharmacia Biotechnology Ltd.)
containing catalase (232 kDa), aldolase (158 kDa), albumin
(67 kDa), ovalbumin (43 kDa), chymotrypsinogen A (25 kDa),
and ribonuclease (13.7 kDa).
Antibodies
The INN-2 mAb (1), INN-22 mAb (2), INN-58 mAb (5),
INN-64 mAb (6), and INN-68 mAb (7) (12) were HPLC-
purified IgG1. Fab fragments of the mAbs were generated
using the Pierce Immunopure Fab kit following the manufac-
turer’s instructions (Pierce Chemical Co., Cheshire, UK). The
mouse IgGs were digested by immobilized papain for 5 h
before the Fc fragment, together with undigested Igs, was
removed by passage over a Protein A column. The compo-
sition of the Fab fractions was examined using SMART size
exclusion chromatography as described above, PAGE, and
Western blotting. The concentration of each Fab/antibody
solution was determined using the Bradford protein assay
following the manufacturer’s instructions (Bradford assay
protein quantification kit; Pierce Chemical Co.).
Surface Plasmon Resonance
Antigen/antibody complex formation was recorded using a
Biacore X biosensor (Biacore, Uppsala, Sweden) and ana-
lyzed using the BIAevaluation 2.1 software. All solutions were
prepared in HEPES-buffered saline (HBS) at pH 7.5 and
passed through the flow cell at a speed of 20 l/min. The
His6-tagged recombinant hCG proteins, as well as all the
Fab fragments, were extensively dialyzed against HBS, pH
7.5, before use. Each binding cycle was composed of four
events. First, the nitrilotriacetic acid chip was cleaned using
20 l of 10% sodium dodecyl sulfate followed by 20 l of
0.1M NaOH. Second, 20 l of 25 mM NiCl was passed through
the flow cell, resulting in an increase of 80 resonance units
(RU) due to the noncovalent binding of the nickel ions. Third,
50 l of the dialyzed baculovirus-derived protein was injected
at a concentration selected to give an increase of 500 RU.
Finally, 50 l of a solution containing the appropriately diluted
Fab fragments was injected into the flow cell. Once the an-
tibody had passed the surface, the formed complex was
washed with HBS at pH 7.5 for an additional 1000 sec to
dissociate bound antibody. A minimum of 15 sensorgrams
was used for the determination of the association and dis-
sociation constants of each antigen/Fab pair. To obtain an
accurate calculation of the kinetic constants, triplicate sen-
sorgrams of five different concentrations for each Fab frag-
ment were obtained. INN-2 was used at concentrations vary-
ing between 8.76  107 M and 8.76  108 M; INN-22 was
used at range between 11.67  107 M and 1.167  107 M;
the concentrations of INN-58 Fab varied between 19 
107 M and 1.58 107 M; only five concentrations of INN-64
Fab (8.84  107 M to 1.77  107 M) were necessary to
establish the association and dissociation rates for the bind-
ing of this antibody to Bac-hCG-WT; and INN-68 was used
at concentrations ranging between 11.2 107 M and 2.24
107 M. All experiments were performed at 25 C. Both the
association and dissociation curves were recorded. Before
1810 Mol Endocrinol, July 2005, 19(7):1803–1811 Charrel-Dennis et al. • Conformation of hCG-R68E Mutant
each analysis, the slow release of the His6-tagged protein
was recorded and subtracted from the sensorgrams showing
the binding characteristics of the antibodies. The sensor-
grams were finally normalized and overlaid before analysis in
a 1:1 Langmuir model using the BIAevaluation 2.1 program.
This program uses nonlinear regression analysis for the de-
termination of rate binding constants for macromolecular
interactions.
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